TargED Biopharmaceuticals

Will you be at JPM Week later this month? We're honored to host a CEO Roundtable discussion at WuXi AppTec's #WuXiGlobalForum alongside #JPM2025. The event will highlight how every innovation story matters. Our CEO, Kristof Vercruysse, is looking forward to the discussions! https://lnkd.in/eJ5m3X_j

📣 Mark your calendars! From 13 to 16 January, 2025, our CEO, Kristof Vercruysse, and Business Development Lead, Martijn Negen, will be attending the prestigious J.P. Morgan Healthcare Conference in San Fransicso, USA. This global event brings together the brightest minds in healthcare and life sciences to drive innovation and collaboration. Kristof and Martijn are eager to connect with industry leaders, discuss transformative ideas, and showcase how TargED is making an impact in the field of thrombosis. Are you attending JPM 2025? We’d love to meet you! Feel free to reach out to Kristof and/or Martijn directly if you would like to schedule a meeting. #JPM2025 #HealthcareInnovation #Networking

📣  TargED Biopharmaceuticals enters clinic with Phase 1 trial of its groundbreaking thrombolytic TGD001 📣 TargED Biopharmaceuticals is pleased to announce it has dosed the first participant with its groundbreaking thrombolytic drug, TGD001. This Phase 1a clinical trial will assess TGD001’s safety and tolerability in healthy volunteers. TGD001 is a first-in-class ‘fusion protein’ drug with a unique two-step mode of action, which offers patients with clotting disorders the potential of a faster, safer and more effective treatment than currently available treatments. Kristof Vercruysse, CEO and co-founder of TargED, commented: “Blood clotting disorders account for around 16 million deaths per year worldwide, almost half of that number from acute ischemic stroke (AIS) alone. But currently available thrombolytics, which break down blood clots, have significant drawbacks which limit their safety, effectiveness and applicability. Because TGD001’s unique mode of action means it does not suffer from the problems of today’s thrombolytics, we believe it will be a safer, more effective and more widely usable treatment – for a wide range of thrombotic disorders. The start of this Phase 1 clinical trial is an important milestone on our journey to reach that objective.” The first safety read-out is expected by mid-2025. TargED then plans to start two proof-of-concept trials in the second half of 2025: a Phase 2a in patients with acute ischaemic stroke (AIS) and a Phase 1b trial in patients with the rare micro-clotting disorder immune-mediated thrombotic thrombocytopenic purpura (iTTP). Read more about the clinical trial in the first comment below! #TGD001 #TargED #clinicalupdate #stroke #acuteischemicstroke #ittp

A few weeks ago, our CEO Kristof had the incredible opportunity to participate in the EIT Health Calling2Scale program, which took us to the thriving hubs of Toronto and Boston. This invaluable experience allowed us to gain fresh insights into the North American markets and build meaningful connections with leaders in healthcare and neuroscience innovation. The program brought together an inspiring group of European companies – each pioneering advancements in areas like epilepsy, Alzheimer’s, and other critical fields. We were honored to exchange insights with remarkable peers including GGTUDE, RebrAIn, Neroes, NeuroBlast, Actipulse Neuroscience® , Bitbrain, NeuroSoV, AURIMOD GmbH, AgenT, mjn-neuro, Maicatech, and BrainTale. The interactions were incredibly rewarding and sparked exciting possibilities for future collaborations.   We are sincerely thankful to the EIT Health and EIT Global Outreach teams for curating this fantastic initiative and for supporting us throughout this journey. We also deeply appreciate the warm welcome extended by the Ontario Brain Institute in Toronto, Advise Connect Inspire, LLC in Boston, and Greenberg Traurig, LLP. These organizations generously shared their expertise and insights, enriching our understanding and experience. Here's to new connections, valuable insights, and a shared commitment to innovation in healthcare and neuroscience! Thank you to everyone who made this journey unforgettable. ✨ #EITHealth #Calling2Scale #HealthcareInnovation #Collaboration

Last week, our Chief Scientific Officer, Steven de Maat, had the privilege of presenting TargED’s latest groundbreaking data at the International Symposium on Neuroprotection and Neurorepair (ISN&N) in Potsdam, Germany. Steven shared insights into our innovative approach to degrading blood clots in both microvascular and macrovascular thrombosis, showcasing how this breakthrough enables us to address and potentially cure many forms of thrombotic diseases. Our cutting-edge research holds significant promise in the treatment of acute ischemic stroke (AIS), where rapid clot degradation can minimize neurological damage and improve patient outcomes. Additionally, it opens new therapeutic possibilities for rare but severe conditions like thrombotic thrombocytopenic purpura (TTP), where targeted clot breakdown could help address the underlying pathology.    We are incredibly proud of our team’s dedication to pushing the boundaries of science and making a meaningful impact in the field of neurorepair. A big thank you to ISN&N for hosting such an inspiring event and providing a platform for collaboration and exchange among global experts. Together, we’re shaping the future of healthcare. #Neuroprotection #Neurorepair #Innovation #Healthcare 

📣 Exciting news! We're thrilled to welcome Anne-Grethe Mortensen to TargED's Board of Directors as a Non-Executive Board member. Anne-Grethe brings over 35 years of leadership experience in the pharmaceutical industry, most recently serving as Chief Marketing Officer & Senior Executive Vice President at Bayer Pharma AG. Her expertise in driving commercial strategy and launching succesful therapies across multiple therapeutic areas will be invaluable as we advance the treatment of thrombosis through our innovative therapy, TGD001, bringing a new level of precision and effectiveness to patient care. #Healthcare #Innovation #Thrombosis

As we look back on an incredible evening at the Prix Galien USA Awards, we are deeply honored to have been selected as a finalist in the Best Start-up category at this prestigious event. It was a memorable night celebrating innovation in life sciences, and we loved the opportunity to meet and connect with so many inspiring people who are driving healthcare forward. A special congratulations to CervoMed, this year’s well-deserved winner! Their achievement is a testament to the incredible work happening across our industry, and we look forward to seeing their impact grow. Thank you to the Prix Galien committee for this recognition – it fuels our passion and commitment to delivering our life-saving therapy to patients around the globe. Here’s to innovation, collaboration, and a future of transformative healthcare! #PrixGalien #LifeSciences #Innovation #Healthcare 

🚀 TargED joins EIT Health’s Calling2Scale Programme We are thrilled to share that TargED has been selected to participate in the highly regarded EIT Health Calling2Scale programme! Between November 10-15, our CEO, Kristof Vercruysse, will be representing us during this North America Roadshow as he travels to Toronto and Boston, connecting with top-tier investors, industry leaders, and partners to showcase our cutting-edge therapy. This is a unique opportunity to expand our global reach and accelerate our mission to bring our life-changing treatment to patients worldwide.🌎 As if that wasn’t enough, Kristof’s North American tour will start off on November 7th in New York, where he will attend the Prix Galien USA Awards as TargED is a nominee in their Best Start-up category! This recognition further highlights our innovative approach and dedication to addressing unmet medical needs. We’re incredibly grateful to our team and partners for their unwavering support. Stay tuned for updates – exciting things are ahead! #EITHealth #Calling2Scale #NorthAmericaRoadshow #BiotechInnovation #PrixGalienUSA #BestStartup #HealthcareInnovation 

🌍 World Thrombosis Day 2024: Advancing Care, Saving Lives On this World Thrombosis Day, we’re reminded of the ongoing fight against thrombosis, a condition that silently affects millions, often with devastating consequences. But awareness and action can change that. At TargED, our focus this year is on progress. We’re proud to be driving the development of our innovative thrombolytic therapy, TGD001, pushing the boundaries of current treatment options. With each step closer to clinical trials, our determination to provide new hope for patients grows stronger. Thrombosis doesn’t discriminate – it can affect anyone. That’s why it’s crucial for us all to stay informed and proactive about prevention, treatment, and the potential future breakthroughs in care. 💡 Our mission: To bring TGD001 to the clinic and provide new treatment options for patients suffering from thrombosis. Together, we can make a real impact! #WorldThrombosisDay #InnovatingHealthcare #ThrombosisAwareness #TGD001

🌿 TargED Team Retreat: A Unique Safari Experience Earlier this week, the entire TargED team embarked on a memorable safari adventure in the beautiful Dutch Veluwe. Not only did we immerse ourselves in nature, but we also held insightful sessions with all our departments combined. A highlight was an inspiring lecture on Stroke by Professor Bart van der Worp. Our stay at a custom tent camp arranged by the fantastic team of TeamTripper | Dutch Safaris, offered the perfect setting to unwind and connect. We also enjoyed an informative wildlife walk with guide Giles Vermeire, who shared his vast knowledge about local species, mushrooms, vegetation, and even taught us how to track animals! After a six-course dinner that we prepared together (with a little help from a professional chef) and a fun quiz, we gathered around the bonfire with a guitar, enjoying some drinks well past midnight. It was the perfect moment to reflect on what an incredible team we have! This retreat will go down in the books as another incredible team experience, leaving us more excited than ever to continue pushing our product towards the clinic! 🚀 #TeamTargED #VeluweSafari #TeamRetreat #InnovationInHealth #Biotech #TeamBuilding